Scott Peterson, PhD, is a Senior Vice President and the head of Research at Seagen, leading a team responsible for advancing a pipeline of innovative ADC and immune oncology drugs to IND, as well as managing ongoing preclinical research on clinical stage assets and marketed drugs. Scott joined Seagen in 2018 after serving as the Chief Scientific Officer at Cascadian Therapeutics where he led the preclinical and translational sciences teams supporting the advancement of the selective HER2 inhibitor tucatinib (TUKYSA) to a pivotal study in HER2+ breast cancer, as well as other programs that advanced into clinical studies including the TIGIT antibody (SEA-TGT) currently being developed by Seagen. Prior to Cascadian, Scott served as Director and Department Head of Oncology Research at Zymogenetics where he led a team focused on exploring mono- and bispecific antibodies targeting cell surface receptors involved in oncogenic signaling pathways. Prior to that, Scott led the cancer discovery research team at ICOS Corporation, which included both small molecule and antibody therapeutic discovery. Scott received his PhD in chemistry (biochemistry) at the University of Colorado, Boulder, and a BSc in Biology at Washington State University.